Your browser is no longer supported. Please, upgrade your browser.
Settings
AFMD [NASD]
Affimed N.V.
Index- P/E- EPS (ttm)-0.62 Insider Own2.79% Shs Outstand114.79M Perf Week-2.36%
Market Cap995.32M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float109.37M Perf Month13.48%
Income-47.20M PEG- EPS next Q-0.11 Inst Own57.10% Short Float6.93% Perf Quarter35.28%
Sales27.00M P/S36.86 EPS this Y-56.50% Inst Trans23.30% Short Ratio2.21 Perf Half Y170.94%
Book/sh0.65 P/B14.63 EPS next Y28.30% ROA-37.70% Target Price14.65 Perf Year340.28%
Cash/sh1.11 P/C8.54 EPS next 5Y- ROE-100.40% 52W Range1.88 - 10.79 Perf YTD63.40%
Dividend- P/FCF- EPS past 5Y- ROI-77.20% 52W High-14.04% Beta2.65
Dividend %- Quick Ratio2.20 Sales past 5Y44.60% Gross Margin- 52W Low393.35% ATR0.80
Employees128 Current Ratio2.20 Sales Q/Q400.00% Oper. Margin- RSI (14)59.77 Volatility9.00% 7.41%
OptionableYes Debt/Eq0.05 EPS Q/Q60.20% Profit Margin- Rel Volume0.82 Prev Close9.51
ShortableYes LT Debt/Eq0.01 EarningsApr 15 BMO Payout- Avg Volume3.43M Price9.27
Recom1.70 SMA209.56% SMA5030.54% SMA20078.70% Volume655,156 Change-2.47%
Mar-31-21Initiated Credit Suisse Outperform $15
Mar-28-19Initiated SVB Leerink Outperform
Aug-28-18Upgrade Jefferies Hold → Buy
Jul-14-17Initiated SunTrust Buy $7
Aug-12-16Downgrade Leerink Partners Outperform → Mkt Perform
May-19-16Downgrade Leerink Partners Outperform → Mkt Perform
Dec-10-15Initiated Laidlaw Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Sep-09-15Initiated Jefferies Hold
Aug-06-15Reiterated Oppenheimer Outperform $14 → $19
Jun-22-15Reiterated Jefferies Buy $12 → $16
Apr-15-21 05:18PM  
12:29PM  
06:30AM  
06:30AM  
Apr-12-21 09:37AM  
06:30AM  
Apr-09-21 02:44PM  
07:04AM  
05:59AM  
Apr-08-21 06:30AM  
Mar-31-21 10:14AM  
06:30AM  
Mar-20-21 03:24AM  
Mar-10-21 05:22PM  
01:50PM  
08:26AM  
06:30AM  
Feb-03-21 08:42AM  
07:31AM  
06:30AM  
Jan-15-21 09:21AM  
Jan-14-21 08:36AM  
Jan-13-21 06:15AM  
Jan-12-21 04:01PM  
Jan-11-21 06:45AM  
06:30AM  
Jan-07-21 06:30AM  
Dec-20-20 01:02AM  
Dec-15-20 08:40PM  
Dec-08-20 08:03AM  
Dec-07-20 10:01AM  
Nov-20-20 07:37AM  
Nov-19-20 04:01PM  
Nov-10-20 02:30PM  
08:40AM  
07:55AM  
07:35AM  
06:30AM  
Nov-09-20 04:01PM  
10:17AM  
08:20AM  
Nov-05-20 04:01PM  
Nov-04-20 04:05PM  
06:30AM  
Nov-03-20 06:30AM  
Oct-29-20 06:32AM  
Oct-26-20 11:55PM  
Oct-20-20 06:30AM  
Oct-14-20 05:15PM  
Oct-06-20 06:30AM  
06:30AM  
Sep-29-20 06:30AM  
Sep-14-20 06:21AM  
Sep-02-20 06:30AM  
Aug-17-20 03:30PM  
Aug-11-20 07:31PM  
07:55AM  
07:29AM  
06:30AM  
Aug-10-20 10:57AM  
Aug-05-20 06:30AM  
Aug-04-20 06:30AM  
Jul-31-20 08:23AM  
Jul-29-20 12:33PM  
Jul-10-20 06:30AM  
Jun-30-20 11:03AM  
Jun-29-20 08:43AM  
Jun-28-20 05:57PM  
Jun-25-20 06:02AM  
Jun-23-20 07:57AM  
07:04AM  
06:30AM  
06:30AM  
Jun-22-20 09:20AM  
Jun-18-20 08:34AM  
Jun-17-20 06:30AM  
Jun-16-20 09:47AM  
06:30AM  
Jun-12-20 02:23AM  
Jun-11-20 06:30AM  
May-29-20 08:05AM  
May-28-20 05:00AM  
May-15-20 05:00AM  
May-03-20 08:12AM  
May-01-20 08:07AM  
Apr-29-20 12:00PM  
Apr-28-20 06:31PM  
08:30AM  
06:35AM  
Apr-16-20 07:30AM  
Apr-02-20 07:57AM  
06:30AM  
Apr-01-20 04:01PM  
Mar-26-20 07:30AM  
Mar-24-20 04:00PM  
Mar-17-20 07:30AM  
Feb-19-20 07:30AM  
Feb-03-20 07:30AM  
Jan-10-20 06:30AM  
Jan-07-20 03:23PM  
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma. The company has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; Roivant Sciences Ltd.; and Roche Holding AG, as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.